First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
摘要:
SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.
[EN] CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS [FR] COMPOSES CHIMIQUES A DOUBLE ACTIVITE, PROCEDES DE LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
[EN] PYRAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] PYRAZOLES POUR LE TRAITEMENT DE MALADIES DÉMYÉLINISANTES
申请人:VERTEX PHARMA
公开号:WO2018106641A1
公开(公告)日:2018-06-14
The invention relates to triazole compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
[EN] CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSES CHIMIQUES A DOUBLE ACTIVITE, PROCEDES DE LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
申请人:UCB SA
公开号:WO2003087064A1
公开(公告)日:2003-10-23
The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
申请人:Provins Laurent
公开号:US20060074068A1
公开(公告)日:2006-04-06
The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.